Lawrence Allen, MD
Internal Medicine · Las Vegas, NVNPI 1174596142
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 143 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 21.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $575 and has fallen 81.3% since, to $108 in 2025.
Across 143 payments — averaging $15.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$481
- Novo Nordisk$201
- AbbVie$195
- Novartis$173
- Lilly USA, LLC$117
- Amgen$109
- plus $984 from 23 others
Across 182 payments — averaging $3731.79 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$250K
- AbbVie$223K
- Janssen Research & Development, LLC$89K
- Biohaven Pharmaceutical Holding Company Ltd.$48K
- Amgen$47K
- Novo Nordisk AS$22K
- plus $1K from 1 others
What the payments were for
- Food & beverage$2,261100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 41 | $481 |
| Novo Nordisk | 12 | $201 |
| AbbVie | 11 | $195 |
| Novartis | 10 | $173 |
| Lilly USA, LLC | 7 | $117 |
| Amgen | 5 | $109 |
| Boston Scientific | 5 | $83 |
| Nabriva Therapeutics, PLC | 5 | $82 |
| Bayer | 5 | $82 |
| AstraZeneca | 6 | $79 |
| Merck | 6 | $78 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $74 |
| Johnson & Johnson | 4 | $57 |
| Amarin Pharma, Inc. | 3 | $52 |
| Sanofi-aventis U.S. LLC | 3 | $49 |
| Eisai Inc. | 2 | $35 |
| IBSA Pharma Inc. | 1 | $35 |
| Boehringer Ingelheim | 2 | $34 |
| Biohaven Pharmaceuticals, Inc. | 2 | $34 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $33 |
| Astellas Pharma US Inc | 2 | $28 |
| Kowa Pharmaceuticals America, Inc. | 1 | $27 |
| Kyowa Kirin, Inc. | 1 | $26 |
| Sumitomo Pharma America, Inc. | 1 | $21 |
| Ultragenyx Pharmaceutical Inc. | 1 | $17 |
| Lucid Diagnostics Inc. | 1 | $16 |
| Otsuka America Pharmaceutical, Inc. | 1 | $16 |
| Irhythm Technologies, Inc. | 1 | $15 |
| Exact Sciences | 1 | $13 |
How this compares
$2,261 in reported general payments places this provider in the 85th percentile of 1,071 internal medicine providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 99 | $149,026 |
| EliquisApixaban | 90 | $90,970 |
| JardianceEmpagliflozin | 29 | $33,667 |
| TradjentaLinagliptin | 22 | $32,373 |
| FarxigaDapagliflozin Propanediol | 22 | $27,104 |
| OzempicSemaglutide | 12 | $22,957 |
| VascepaIcosapent Ethyl | 28 | $17,126 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 21 | $12,458 |
| MyrbetriqMirabegron | 26 | $11,722 |
| PremarinEstrogens, Conjugated | 13 | $7,597 |
| Repatha SureclickEvolocumab | 12 | $7,591 |
| BelsomraSuvorexant | 15 | $6,294 |
| Telmisartan | 104 | $3,036 |
| Ezetimibe | 89 | $2,792 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 62 | $2,509 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $117 | $149,02699 claims |
| PfizerEliquis, Premarin | $481 | $98,567103 claims |
| Boehringer IngelheimJardiance, Tradjenta | $34 | $66,04051 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $79 | $39,56243 claims |
| Novo NordiskOzempic | $201 | $22,95712 claims |
| Astellas Pharma US IncMyrbetriq | $28 | $11,72226 claims |
| MerckBelsomra | $78 | $6,29415 claims |
| AbbVieSynthroid | $195 | $1,56630 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,071 internal medicine providers in Nevada.
Other internal medicine in Las Vegas
- Kevin DunsmoorLas Vegas$241K
- Robert ChiascioneLas Vegas$174K
- Dino GonzalezLas Vegas$126K
- Rosanne SugayLas Vegas$63K
- Chad HallLas Vegas$42K
- Zubin DamaniaLas Vegas$40K
- Audrey Sue CruzLas Vegas$34K
- Bashab BanerjiLas Vegas$26K
- Amaan ShafiLas Vegas$25K
- Sassan KavehLas Vegas$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.